Safety of aesthetic dermatological procedures in breast cancer patients: myths and reality

Baichorov E.A.; Saromytskaya A.N.

doi:https://doi.org/10.17116/klinderma202221051687

Close metadata

Recommended articles:

Abobotulinumtoxin A injections for the chronic sialorrhea correction in children: Russian retrospective multicenter study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):53-61

The possibilities of predicting and reducing the risk of breast cancer in women against the background of the use of assisted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64

Neoadjuvant drug therapy and oncological outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Oncology. 2025;(1):5-12

Immunogenicity of botulinum toxin products: the emergence of resistance and ways to overcome it. Plastic Surgery and Aesthetic Medicine. 2025;(1):125-134

The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10

Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant polychemotherapy depending on Ki-67 levels. P.A. Herzen Journal of Oncology. 2025;(2):13-18

Repeated breast reconstruction after previous complications. Pirogov Russian Journal of Surgery. 2025;(6):51-57

Guidelines for assessing the quality of mammographic images. Russian Journal of Preventive Medicine. 2025;(6):21-32

Hematological indicators of the systemic inflammatory response in the prognosis of luminal HER2-negative breast cancer patients undergoing surgery followed by adjuvant therapy. P.A. Herzen Journal of Oncology. 2025;(3):31-38

Hemostasis disorders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2025;(3):39-44

Abstract:

The peak incidence of breast cancer in females coincides with the peak of treatment demand for aesthetic procedures and falls at the age of 35-55 years. Currently, women facing this diagnosis have a high chance of being cured and achieving high survival rates. On the one hand, there is an obvious need to restore the quality of life after the difficult treatment; on the other hand, there are doubts about the safety of aesthetic procedures and their possible effects on both the cancer process and the anti-tumor treatment. Systematic analysis of English-language studies regarding the safety of botulinum toxin A and soft tissue fillers in breast cancer patients shows that the drugs of both groups are safe for use in patients in this group and even are in the experimental stage of research as anti-tumor drugs. While there is no time limit for botulinum toxin A agents, in the case of soft tissue fillers, it is recommended to wait 6-12 months after the end of chemotherapy, radiotherapy, or targeted therapy (monoclonal antibodies).

Keywords:

breast cancer

botulinum toxin A

botulinum toxin complications

soft tissue fillers

filler complications

Authors:

Baichorov E.A.

Stavropol Medical University

Saromytskaya A.N.

«Professional» clinics

Received:

19.12.2021

Accepted:

11.08.2022

Close metadata

References:

Soare GR, Soare CA. Immunotherapy for Breast Cancer: First FDA Approved Regimen. Discoveries. 2019;7(1):e91. https://doi.org/10.15190/d.2019.4
Zielonke N, Kregting LM, Heijnsdijk EA, Veerus P, Heinävaara S, McKee M. and EU‐TOPIA collaborators. The potential of breast cancer screening in Europe. International Journal of Cancer. 2021;148(2):406-418. https://doi.org/10.1002/ijc.33204
Aksel EM, Vinogradova NN. Statistics of malignant neoplasms of female reproductive organs. Onkoginekologiya. 2018;3:64-78. (In Russ.).
Mattiuzzi C, Lippi G. Current cancer epidemiology. Journal of Epidemiology and Global Health. 2019;9(4):217. https://doi.org/10.2991/jegh.k.191008.001
Guo F, Kuo YF, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124(17):3500-3509. https://doi.org/10.1002/cncr.31638
Caparica R, Lambertini M, Pondé N, Fumagalli D, Azambuja E, Piccart M. Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Therapeutic Advances in Medical Oncology. 2019;11:1758835919827714. https://doi.org/10.1177/1758835919827714
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363-385. https://doi.org/10.3322/caac.21565
Kaprin AD, Starinsky VV, Gretsova OP, Petrova GV, Samsonov YuV, Shakhzadova AO, Prostov YuI, Prostov MYu. Population Register of cancer patients in the Russian Federation. Panorama obshchestvennogo zdravookhraneniya. 2019;5(1):99-102. (In Russ.).
Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME, Restorative Oncodermatology: Diagnosis and Management of Dermatologic Sequelae from Cancer Therapies, Journal of the American Academy of Dermatology. 2021;85(3):693-707. https://doi.org/10.1016/j.jaad.2020.08.005
Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, Miglioretti DL. Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Annals of Internal Medicine. 2012;156(9): 635-648. https://doi.org/10.7326/0003-4819-156-9-201205010-00006
Nindrea RD, Aryandono T, Lazuardi L. Breast cancer risk from modifiable and non-modifiable risk factors among women in Southeast Asia: A meta-analysis. Asian Pacific J Cancer Prev. 2017;18(12):3201-3206. https://doi.org/10.22034/APJCP.2017.18.12.3201
Ma Y, He B, Jiang M, Yang Y, Wang C, Huang C, Han L. Prevalence and risk factors of cancer-related fatigue: A systematic review and meta-analysis. International Journal of Nursing Studies. 2020;111:103707. https://doi.org/10.1016/j.ijnurstu.2020.103707
Escala-Garcia M, Morra A, Canisius S, Chang-Claude J, Kar S, Zheng W, Schmidt MK. Breast cancer risk factors and their effects on survival: A Mendelian randomisation study. BMC Medicine. 2020;18(1):1-10. https://doi.org/10.1186/s12916-020-01797-2
Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley, Antoniou AC. BOADICEA: A comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine. 2019;21(8):1708-1718. https://doi.org/10.1038/s41436-018-0406-9
American Society of Plastics Surgeons. 2020 Plastic Surgery Statistics Report. Am Soc Plast Surg. 2020;1-23. Accessed December 11, 2021. https://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Plastic+Surgery+Statistics+Report#1
Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Seminars in Cutaneous Medicine and Surgery. 2002;48(5):299-322.
Manturova NE, Chaikovskaya EA, Timerbaeva SL. Botulinum toxin preparations: what do we have and what do we see on the horizon? Plastic Surgery and Aesthetic Medicine. 2020;2:70-80. (In Russ.). https://doi.org/10.17116/plast.hirurgia202002170
Landau M, Nestor MS, de Almeida AT, Al-Niaimi F. Botulinum toxin complications in registered and off-label aesthetic indications. J Cosmet Dermatol. 2020;19(10):2484-2490. https://doi.org/10.1111/jocd.13667
US Food and Drug Administration. MEDICATION GUIDE BOTOX®, BOTOX® Cosmetic (Boe-tox) (onabotulinumtoxinA) for Injection. What is the most important information I should know about BOTOX and BOTOX Cosmetic? BOTOX and BOTOX Cosmetic may cause serious side effects that can be life threatening. 2016. Accessed December 11, 2021. https://www.fda.gov/downloads/drugs/drugsafety/ucm176360.pdf
Cohen JL, Scuderi N. Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use: A systematic review. Aesthetic Surgery Journal. 2017;37(1): 32-44. https://doi.org/10.1093/asj/sjx010
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ open. 2019;9(7):e027953. https://doi.org/10.1136/bmjopen-2018-027953
Yang W, Li G. The Safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: A systematic review and meta‐analysis. Journal of cosmetic dermatology. 2020;19(4):799-808. https://doi.org/10.1111/jocd.13139
Araklitis G, Cardozo L. Safety issues associated with using medication to treat overactive bladder. Expert Opin Drug Saf. 2017;16(11):1273-1280. https://doi.org/10.1080/14740338.2017.1376646
Bandala C, Miliar-Garcia A, Mejía-Barradas CM, Anaya-Ruiz M, Luna-Arias JP, Bazán-Méndez CI, Lara-Padilla E. Synaptic vesicle protein 2 (SV2) isoforms. Asian Pacific Journal of Cancer Prevention. 2012;13(10):5063-5067. https://doi.org/10.7314/APJCP.2012.13.10.5063
Bandala C, Perez-Santos JLM, Lara-Padilla E, Lopez MGD, Anaya-Ruiz M. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pacific J Cancer Prev. 2013;14(2):891-894. https://doi.org/10.7314/APJCP.2013.14.2.891
Bandala C, Cortés-Algara AL, Mejía-Barradas CM, Ilizaliturri-Flores I, Dominguez-Rubio R, Bazán-Méndez CI, Lara-Padilla E. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. International Journal of Clinical and Experimental Pathology. 2015 July 01; 8(7):8411-8418. www.ijcep.com/ISSN:1936-2625/IJCEP0010657
Hajighasemlou S, Alebouyeh M, Rastegar H, Manzari MT, Mirmoghtadaei M, Moayedi B, Farajollahi, MM. Preparation of immunotoxin herceptin-botulinum and killing effects on two breast cancer cell lines. Asian Pacific Journal of Cancer. 2015;16(14):5977-5981. https://www.scopus.com/inward/record.uri?eid=2-s2
Layeeque R, Hochberg J, Siegel E, Kunkel K, Kepple J, Henry-Tillman RS, Klimberg VS. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Annals of Surgery. 2004;240(4):608-614. https://doi.org/10.1097/01.sla.0000141156.56314.1f
Stubblefield MD, Levine A, Custodio CM, Fitzpatrick, T. The role of botulinum toxin type A in the radiation fibrosis syndrome: A preliminary report. Archives of Physical Medicine and Rehabilitation. 2008;89(3):417-421. https://doi.org/10.1016/j.apmr.2007.11.022
Lo KK, Aycock JK. A blinded randomized controlled trial to evaluate the use of botulinum toxin for pain control in breast reconstruction with tissue expanders. Annals of Plastic Surgery. 2015;74(3):281-283.
Rostami R, Mittal SO, Radmand R, Jabbari B. Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins. 2016; 8(1):22. Received: 21 August 2015. https://doi.org/10.3390/toxins8010022
De Groef A, Devoogdt N, Van Kampen M, Nevelsteen I, Smeets A, Neven P, et al. Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial. Arch Phys Med Rehabil. 2018;99(7):1342-1351. https://doi.org/10.1016/j.apmr.2017.12.032
Wollina U, Brzezinski P. Aesthetic dermatology: What’s new, what’s true? Dermatol Ther. 2019;32(4):2-7. https://doi.org/10.1111/dth.12623
Funt D, Pavicic T. Dermal fillers in aesthetics: An overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295-316. https://doi.org/10.2147/CCID.S50546
Shamban A. Safety and Efficacy of Facial Rejuvenation with Small Gel Particle Hyaluronic Acid with Lidocaine and Abobotulinumtoxin A in Post-Chemotherapy Patients: A Phase IV Investigator-initiated Study. J Clin Aesthet Dermatol. 2014;7(1):31-36. PMCID: PMC3930538. PMID: 24563694.
Coughlin A, Gray ML, Westra WH, Teng MS, Rosenberg JD. Dermal Filler Presenting as Parotid Mass: A Case Report. Head Neck Pathol. 2021; 15(2):638-641. https://doi.org/10.1007/s12105-020-01197-1
Hibler BP, Yan BY, Marchetti MA, Momtahen S, Busam KJ, Rossi AM. Facial swelling and foreign body granulomatous reaction to hyaluronic acid filler in the setting of tyrosine kinase inhibitor therapy. Journal of the European Academy of Dermatology and Venereology: JEADV. 2018;32(6):e225. https://doi.org/10.1111/jdv.14749
Sahiner N, Suner SS, Kurt SB, Can M, Ayyala RS. HA particles as resourceful cancer, steroidal and antibiotic drug delivery device with sustainable and multiple drug release capability. J Macromol Sci Part A Pure Appl Chem. 2021;58(3):145-155. Published online: 12 Oct 2020. https://doi.org/10.1080/10601325.2020.1832518
Heydenrych I, de Boulle K, Kapoor KM, Bertossi D. The 10-Point Plan 2021: Updated concepts for improved procedural safety during Facial Filler Treatments. Clin Cosmet Investig Dermatol. 2021;14:779-814. https://doi.org/10.2147/CCID.S315711
Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter, J. Significant impairment in immune recovery following cancer treatment. Nursing Research. 2009;58(2):105. https://doi.org/10.1097/NNR.0b013e31818fcecd
Carvalho HDA, Villar RC. Radiotherapy and immune response: The systemic effects of a local treatment. Clinics. 2018;73(1):e557s. https://doi.org/10.6061/clinics/2018/e557s